NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed from Pathway Diagnostics the underlying technology used in its co-receptor tropism HIV assay, Quest said today.
The non-exclusive license covers the heteroduplex tracking technology used in Pathway’s SensiTrop test. Quest said that a molecular-based assay for co-receptor tropism will help physicians personalize HIV therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.